[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"right-ventricular-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:right-ventricular-dysfunction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,77,107,133,155,178,211,236,267,297,318,343],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100473856","phase-2-inhaled-milrinone-and-epoprostenol-for-the-prevention-of-difficult-cardiac-pulmonary-bypass-separation-100473856",false,"NCT05450328","Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation","Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation: A Randomized, Double-blind, Controlled Trial","MILAN","Inclusion Criteria:\n\n\\- Only patients undergoing cardiac surgery with CPB and aged 18 years and older will be included in this study.\n\nExclusion Criteria:\n\n* The presence of congenital cardiomyopathy, which the correction is the primary objective of the proposed surgery. For example, a patient who requires surgery for atrial septal defect closure only would not be eligible for the study. On the other hand, a patient who undergoes this same surgery in addition to a valve replacement, for example, would be eligible to participate in the study.\n* Heart transplant or ventricular assist device surgery\n* Urgent surgery including hemodynamic instability requiring vasopressor agents upon arrival in the operating room\n* A contraindication to transesophageal ultrasound monitoring or the presence of an unstable cervical spine.\n* Presence of a contraindication related to Epoprostenol or Milrinone administration such as a documented left ventricular or right ventricular outflow tract obstruction, a severe unaddressed aortic stenosis, or a documented allergy to either of these two molecules.",true,"ALL","18 Years",{"count":21,"type":22},141,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","In cardiac surgery, the presence of pulmonary hypertension (PH) is a prognostic factor associated with increased mortality and morbidity. In this context, one of the main causes of PH is related to reperfusion ischemia during weaning from extracorporeal circulation (CPB). One of the consequences of PH is right ventricular dysfunction. During weaning from CPB, the development of a right ventricular dysfunction is associated with increased requirements for vasopressor and inotropic agents, duration of mechanical ventilation, prolonged intensive care and hospital stay, and increased mortality compared with patients with left ventricular (LV) dysfunction. The management of patients with PH with or without right ventricular (RV) dysfunction relies on several strategies such as the administration of intravenous and inhaled agents, or mechanical ventricular support. Among those agents, the administration of inotropes or pulmonary vasodilators such as epoprostenol, milrinone and nitric oxide are among the most widely used treatments recommended by the Canadian Cardiovascular Society. At the Montreal Heart Institute, inhaled epoprostenol and milrinone are routinely administered to patients with PH or LV dysfunction in the perioperative setting. Despite the frequent use of inhaled epoprostenol and milrinone, Health Canada has not yet approved the use of these molecules.\n\nThe primary objective of this multicenter, double-blind, randomized clinical trial is to evaluate the clinical efficacy of the combined administration of inhaled epoprostenol and milrinone in a cardiac surgery setting. This trial will compare the clinical outcome of 71 patients who will receive inhaled epoprostenol and milrinone before the start of bypass surgery to 71 patients who will receive a placebo before the start of the CPB. The primary clinical outcome is the proportion of patients with an \"unsuccessful\" CPB weaning defined by the use of an inotrope +\u002F- vasopressor agent or the use of mechanical circulatory support or a return to bypass grafting for hemodynamic reasons.\n\nThis clinical trial will evaluate the clinical efficacy of the combination of inhaled agents in a cardiac surgery setting. Therefore, if the results of this study are positive, the combination of inhaled epoprostenol and milrinone will optimize the management of patients with pulmonary hypertension with or without a right ventricular dysfunction.",[28,29],"Right Heart Failure","Right Ventricular Dysfunction",[31,29,32,33],"Cardiac Surgery","Cardiopulmonary Bypass","Inhaled Therapy","RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2025-12-10",{"date":42,"type":22},"2028-12-01",{"name":44,"class":45},"Montreal Heart Institute","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100634279","right-ventriculo-arterial-coupling-during-fluid-loading-in-icu-patients-100634279","NCT07537621","Right Ventriculo-Arterial Coupling During Fluid Loading in ICU Patients","Prospective Observational Study of Right Ventriculo-arterial Coupling Changes During Fluid Loading and Their Relationship With Congestion Parameters in Critically Ill Adults","RVPA-FLICU","Inclusion criteria:\n\n* Critically ill hospitalized patients\n* Age ≥ 18 years\n* Patients undergoing fluid loading at the discretion of the attending physician, following prediction of fluid responsiveness using any recommended maneuver or dynamic parameter, in the setting of acute circulatory failure requiring vasopressor support and\u002For mean arterial pressure \\\u003C 65 mmHg (or a decrease of ≥ 30 mmHg from baseline in patients with chronic hypertension), and\u002For other signs of hemodynamic instability (tachycardia, mottling, oliguria, hyperlactatemia)\n* Affiliated with a national health insurance system\n\nExclusion criteria :\n\n* Formal refusal from the patient or legally representative after information\n* Patients transferred from another intensive care unit\n* Pregnant or postpartum patients\n* Acute respiratory distress (defined as respiratory rate ≥ 35 breaths\u002Fmin and\u002For signs of increased work of breathing)\n* Ongoing acute coronary syndrome\n* Acute or pulmonale (defined by right ventricular dilation associated with paradoxical septal motion related to an abrupt increase in right ventricular afterload)\n* Primary pulmonary arterial hypertension\n* Intra-abdominal hypertension (intravesical pressure \\> 15 mmHg)\n* Poor echogenicity precluding adequate echocardiographic assessment of the right ventricle\n* Severe valvular heart disease or early postoperative period following valvular surgery",{"count":56,"type":22},100,"OBSERVATIONAL","Preload responsiveness and venous congestion have largely been investigated independently in recent literature. However, recent data report a similar incidence of venous congestion regardless of fluid responsiveness status, challenging the concept of a linear continuum between preload independence and fluid intolerance. These findings support the need for a more individualized hemodynamic management strategy that takes venous congestion risk into account.\n\nThe right ventricle plays a central role in this framework. Its function is to maintain an adequate venous return pressure gradient to ensure cardiac output while limiting upstream venous congestion, under strong dependence on its afterload. In physiological conditions, the right ventricle adapts to changes in afterload by increasing contractility to preserve right ventriculo-arterial coupling and optimize its performance.\n\nIn chronic cardiopulmonary diseases, right ventriculo-arterial uncoupling is a well-established prognostic factor, including the presence of occult uncoupling revealed by fluid loading. In critically ill patients, right ventricular systolic dysfunction associated with venous congestion-defining right heart failure-is strongly associated with increased mortality, as is right ventriculo-arterial uncoupling itself.\n\nTo support the concept of fluid tolerance, the investigators hypothesize that impairment of right ventriculo-arterial coupling may exist or occur during fluid loading in critically ill patients, independently of preload responsiveness, and may be associated with worsening upstream venous congestion.",[60,29,61],"Shock","Venous Congestion",[63,64,65,66,67],"Right ventriculo-arterial coupling","Fluid loading","Venous congestion","VEXUS score","Critical care echocardiography","2026-06-09",{"date":70,"type":38},"2026-06-10",{"date":72,"type":38},"2026-06-03",{"date":74,"type":22},"2029-06-04",{"name":76,"class":45},"CHU de Reims",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100634071","comparing-the-effects-of-newer-pacemakers-and-their-effects-on-the-heart-and-valve-function-in-the-short-term-100634071","NCT07534917","Comparing the Effects of Newer Pacemakers and Their Effects on the Heart and Valve Function in the Short-term.","Left Bundle Branch Area Pacing Versus Right Ventricular Leadless Pacing: Acute Effects on Biventricular and Tricuspid Valve Function","LvL-PACE","Inclusion Criteria:\n\n* All patients aged ≥18 referred for a permanent pacemaker at a single centre (Guys and St. Thomas' NHS Foundation Trust, UK) with high degree AV block, including Mobitz II and complete heart block, or scheduled AV node ablation, and LVEF ≥50%.\n\nExclusion Criteria:\n\n* LVEF \\\u003C50%, severe TR, severe RV dysfunction, clinically unstable AV block requiring temporary pacing or isoprenaline infusion, left bundle branch block, previous TV annuloplasty or replacement, aortic valve replacement, life expectancy \\\u003C1 year, end-stage renal failure, contraindication to cardiac MRI, CT or TOE, pregnancy, contraindication to anticoagulation, peripheral vascular disease precluding insertion of femoral catheters and insufficient capacity to consent to the study.",{"count":86,"type":22},20,"Conventional pacemakers involve placing a lead through a valve into the bottom right chamber of the heart. Research has shown that this approach is associated with an increased risk of valve dysfunction, mortality, and impairment of cardiac function.\n\nNewer pacemakers, such as leadless pacemakers and pacemakers that engage directly with the heart's native conduction system (known as left bundle branch pacemakers), are increasingly being adopted. However, the impact of these newer pacing technologies on cardiac function and the tricuspid valve, as well as how they compare with each other, remains unclear.\n\nThe investigators aim to study the impact of leadless pacemakers and left bundle branch pacemakers on cardiac function and the tricuspid valve by conducting an acute study in addition to the routine pacemaker implantation procedure for which participants have been referred. Both procedures will be performed during a single session under general anaesthesia. Outcomes from this study will improve understanding of how these pacing technologies affect cardiac and valvular function and how they compare with each other. These findings will help guide decision-making regarding the optimal type of pacemaker to adopt, particularly for patients at greatest risk of developing tricuspid valve dysfunction or impaired cardiac function.",[89,90,29],"Pacemaker-Induced Cardiomyopathy","Tricuspid Regurgitation",[92,93,94,95,96],"leadless pacemaker","left bundle branch area pacing","pacemaker-induced cardiomyopathy","tricuspid regurgitation","right ventricular dysfunction","NOT_YET_RECRUITING","2026-06-04",{"date":100,"type":38},"2026-06-08",{"date":102,"type":22},"2026-07-01",{"date":104,"type":22},"2029-06-01",{"name":106,"class":45},"Guy's and St Thomas' NHS Foundation Trust",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":18,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":46},"100508144","phenotyping-resting-and-exertional-right-ventricular-dysfunction-among-patients-with-chronic-obstructive-pulmonary-disease-100508144","NCT05896579","Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* COPD (determined by ratio of forced expiratory volume in 1 second to forced vital capacity \\[FEV1\u002FFVC\\] \\\u003C0.7)\n* Age \\>= 40 years\n\nExclusion Criteria:\n\n* Exacerbation of COPD in the 3 months prior to enrollment\n* Change in COPD therapy in the 3 weeks prior to enrollment\n* Requirement of \\>6 LPM supplemental oxygen at rest\n* Requirement of \\>10 LPM supplemental oxygen with exertion\n* Active\u002Funcontrolled cardiovascular disease (e.g. hypertension with blood pressure \\>150\u002F100 despite antihypertensives; coronary artery disease with angina; left ventricular ejection fraction ≤40%; arrhythmia; pulmonic, mitral or aortic valvular abnormality greater than mild in severity; tricuspid regurgitation greater than moderate in severity)\n* Volume overload (jugular vascular distension or greater than trace peripheral edema)\n* World Health Organization Functional Class IV\n* Known pulmonary hypertension with mean pulmonary artery pressure \\>45 mmHg\n* Untreated severe obstructive sleep apnea or obesity hypoventilation syndrome\n* Active malignancy (other than skin)\n* Medical conditions that limit exercise on an upright stationary bicycle (e.g. severe osteoarthritis, imbalance\u002Fgait instability, etc.)\n* Pregnancy\n* Body mass index \\\u003C18 or \\>40\n* Hematocrit \\\u003C25% or \\>55%\n* For invasive CPET, chronic anticoagulation that is unable to be held for the study visit\n* For invasive CPET, forced expiratory volume in 1 second of \\\u003C20%","40 Years",{"count":115,"type":22},60,[117],"NA","This study plans to learn about heart function among individuals with chronic obstructive pulmonary disease (COPD). In particular, the investigators want to understand the different patterns of right ventricular response during rest and moderate- vs high-intensity exercise. By identifying patterns of right ventricular dysfunction, this study will help identify better treatments for patients with COPD in the future.",[120,121,29,122,123],"COPD","Pulmonary Hypertension","Exercise","Exercise Training","2026-05-04",{"date":126,"type":38},"2026-05-08",{"date":128,"type":38},"2023-08-22",{"date":130,"type":22},"2030-08",{"name":132,"class":45},"University of Colorado, Denver",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":46},"100520208","phase-2-repurposing-valsartan-may-protect-against-pulmonary-hypertension-100520208","NCT06053580","Repurposing Valsartan May Protect Against Pulmonary Hypertension","REVAMP-PH","Inclusion Criteria:\n\n1. Male or female, age 18 to 80\n2. WHO Group 1 Pulmonary Arterial Hypertension\n3. NYHA Functional Class II, III, or IV at screening (Appendix 2 for Functional Class Decision Aid)\n4. Right heart catheterization within five years demonstrating a mean pulmonary arterial pressure of ≥25 mmHg, occlusion pressure of ≤15 mmHg, and resistance ≥ 3 wood units\n5. Participants with a right heart catheterization within five years demonstrating a mean pulmonary arterial pressure of ≥ 25 mmHg and occlusion pressure of 15 - 20 mmHg will be considered for inclusion if the pulmonary vascular resistance ≥ 9 wood units and they are being treated with pulmonary arterial hypertension specific therapy\n6. Able to walk with\u002Fwithout a walking aid for a distance of at least 50 meters\n\nExclusion Criteria:\n\n1. Pregnant or lactating\n2. Non-group 1 pulmonary hypertension or veno-occlusive disease\n3. History of interstitial lung disease, unless subject has collagen vascular disease and has pulmonary function testing conducted within 12 months demonstrating a total lung capacity or vital capacity of ≥ 60 %\n4. Has received or will receive an investigational drug, device, or study within 30 days or during the course of study\n5. ACE-inhibitor, ARB or ARNI use within 30 days of randomization.\n6. Left sided myocardial disease as evidenced by left ventricular ejection fraction \\\u003C 40%\n7. Any other clinically significant illness or abnormal laboratory values (measured during the Screening period) that, in the opinion of the Investigator, might put the subject at risk of harm during the study or might adversely affect the interpretation of the study data\n8. Anticipated survival less than 1 year due to concomitant disease\n9. Allergy or angioedema with ACE-inhibitor use\n10. Potassium \\>5mEq\u002FL or sCr \\>2mg\u002FdL at screening\n11. SBP \\\u003C90mmHg at screening","80 Years",{"count":115,"type":22},[25],"This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.",[145,28,29,146],"Pulmonary Arterial Hypertension","Pulmonary Vascular Disorder","2026-04-30",{"date":124,"type":38},{"date":150,"type":38},"2024-02-28",{"date":152,"type":22},"2027-07-01",{"name":154,"class":45},"University of Washington",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":46},"100466123","early-phase-1-impact-of-iron-supplementation-on-right-ventricular-function-and-exercise-performance-in-hypoxia-100466123","NCT05349630","Impact of Iron Supplementation on Right Ventricular Function and Exercise Performance in Hypoxia","Impact of Iron Supplementation on Right Ventricular Function and Exercise Performance in Hypoxia (A Sub-Study)","Inclusion Criteria:\n\n* Age 18 - 60\n* For women, premenopausal status\n\nExclusion Criteria:\n\n* Active cardiovascular or pulmonary disease (e.g. hypertension, coronary artery disease, cardiomyopathy, arrhythmia, valvular abnormalities, diabetes, peripheral vascular disease, tobacco use, chronic obstructive pulmonary disease, asthma, interstitial lung disease, restrictive lung disease, or pulmonary hypertension)\n* Use of cardiac- or pulmonary-related medications\n* Prior history of high altitude pulmonary edema or high altitude cerebral edema\n* Body mass index \\\u003C 18.5 or \\> 30\n* Anemia\n* Iron deficiency\n* Iron supplementation (oral or intravenous) in the preceding 60 days\n* Systemic anticoagulation or aspirin use that cannot be temporarily held for the study\n* Pregnancy\n* Non-cardiopulmonary disorders that adversely influence exercise ability (e.g. arthritis or peripheral vascular disease)\n* Dedicated athletic training (defined here as spending \\>9 hours per week in vigorous physical activity \\[≥6 mets\\])\n* Regular high-altitude exercise (defined here as engaging in vigorous physical activity \\[≥1 hour at ≥6 mets\\] at ≥8,000 ft for \\>2 days per week over the preceding 4 weeks)\n* Residence at ≥8,000 ft for 3 or more consecutive nights in the preceding 30 days","60 Years",{"count":164,"type":22},5,[166],"EARLY_PHASE1","The purpose of this study is to determine if taking iron supplement pills improves exercise performance in low-oxygen conditions.",[29,169],"Hypoxia","2026-04-27",{"date":172,"type":38},"2026-04-29",{"date":174,"type":22},"2028-03",{"date":176,"type":22},"2030-05",{"name":132,"class":45},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":186,"targetDuration":188,"studyType":57,"phases":4,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":46},"100613884","right-ventricular-function-changes-after-cied-implantation-the-right-cied-study-100613884","NCT07272395","Right Ventricular Function Changes After CIED Implantation: The RIGHT-CIED Study","Monitoring Right Ventricular Function in Patients Undergoing Implantable Cardiac Electronic Device (CIED) Therapy: A Multimodal Imaging and Biomarker-Based Approach","RIGHT-CIED","Inclusion Criteria\n\n* Adults aged 18 years or older.\n* Scheduled to undergo implantation of a clinically indicated pacemaker, ICD, or CRT device.\n* Able to undergo transthoracic echocardiography, VEXUS ultrasound assessment, and non-contrast cardiac MRI.\n* Able to provide written informed consent.\n\nExclusion Criteria\n\n* Contraindication to cardiac MRI (e.g., severe claustrophobia or MRI-unsafe implanted material).\n* Inability to undergo echocardiography or ultrasound assessment.\n* Known pulmonary arterial hypertension (Group 1 PH).\n* Significant congenital heart disease.\n* Patients with mechanical or bioprosthetic heart valve replacement\n* Severe left-sided valvular disease (severe AS or severe MR).\n* Chronic kidney disease stage 4 or 5 (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²).\n* End-stage renal disease requiring dialysis.\n* Primary hyperparathyroidism.\n* Hypophosphataemia or hyperphosphataemia requiring treatment.\n* Active or uncontrolled bone metabolism disorders (e.g., osteomalacia, Paget's disease).\n* Recent fracture or major orthopaedic surgery within the past 3 months.\n* Active systemic inflammatory or autoimmune disease.\n* Active malignancy or malignancy requiring ongoing treatment.\n* Active infection at the time of enrolment.\n* Pregnancy or breastfeeding.\n* Haemodynamic instability at the time of enrolment.\n* Expected survival less than 6 months due to non-cardiac conditions.\n* Inability to provide informed consent.",{"count":187,"type":22},40,"12 Months","This study aims to understand how the right side of the heart changes in people who receive an implantable cardiac electronic device (CIED), such as a pacemaker, ICD, or CRT device. The right ventricle (RV) can sometimes be affected after these devices are placed, but the reasons and timing are not well understood.\n\nTo investigate this, we will examine participants at two time-points: before their device is implanted and again six months later. At each visit, we will assess heart function using echocardiography, a non-contrast cardiac MRI scan, and an ultrasound score of venous congestion called the VEXUS score. We will also take a small blood sample to measure a biomarker called FGF-23, which may reflect changes in heart function.\n\nThe study does not involve any experimental treatment, and all implanted devices are part of routine medical care. The imaging tests and blood samples are for research purposes only. By comparing the measurements before and after device implantation, we hope to better understand how CIEDs influence right-sided heart function and whether imaging findings are related to changes in blood biomarkers.",[29],[96,192,193,194,195,196,197,198,199,61,200,201],"right ventricular function","Cardiac Implantable Electronic Device","Implantable Cardioverter-Defibrillator","pacemaker","Cardiac Resynchronisation Therapy","Cardiac Magnetic Resonance Imaging","Echocardiography","VExUS","Fibroblast Growth Factor 23","Brain Natriuretic Peptide","2025-12-08",{"date":204,"type":38},"2025-12-16",{"date":206,"type":38},"2025-08-15",{"date":208,"type":22},"2026-11-25",{"name":210,"class":45},"Istanbul University - Cerrahpasa",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":164},"100559925","phase-2-feasibility-trial-for-a-right-ventricular-failure-platform-trial-100559925","NCT06570473","Feasibility Trial for a Right Ventricular Failure Platform Trial","Feasibility Trial for the Canadian Right Ventricular AdaptiVE (CRAVE) Platform for Therapies Targeting Right Ventricular Failure","CRAVE","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Able to provide informed consent.\n3. Able to comply with all study procedures.\n4. History of RV dysfunction or RHF secondary to any of:\n\n   a. Group 1 PH, pulmonary arterial hypertension b. Group 2 PH, left heart disease with normal left ventricular ejection fraction (LVEF) \\> 50% and a previous RHC demonstrating combined pre and post-capillary PH, defined as: i. mPAP \\>20 mmHg ii. PAWP \\> 15 mmHg iii. PVR\\> 2 WU c. Group 3 PH d. Group 4 PH, chronic thromboembolic PH that is either persistent after pulmonary endarterectomy or inoperable due to distal disease.\n5. Symptomatic with current NYHA Functional Class II-IV\n6. Biomarker and 2D echocardiogram evidence of RV dysfunction within 3 months:\n\n   1. NT-proBNP \\>300 ng\u002FL and qualitative evidence of at least 'mild' RV dysfunction on echocardiography OR NT-proBNP\\\u003C300 ng\u002FL and qualitative evidence of at least moderate RV dysfunction and\u002For dilatation on 2D echocardiogram AND\n   2. A quantitative 2D echocardiogram with evidence of RV dysfunction defined as having both of the following:\n\n   i. TAPSE ≤18 mm ii. RV dilatation (RV diameter \\> 42 mm at the base).\n7. Receiving loop diuretics or mineralocorticoid receptor antagonists for at least 4 weeks.\n8. Access to an iOS or android smart phone or tablet.\n\nExclusion Criteria:\n\n1. Estimated glomerular filtration rate (eGFR) \\\u003C30 ml\u002Fmin.\n2. LVEF \\\u003C 50%\n3. Normal RV size and function\n4. Severe aortic or mitral valvular disease\n5. Moderate or severe hepatic dysfunction (Child-Pugh Class B or C)\n6. Participants requiring augmentation of diuretics or otherwise not meeting definition for clinical stability\n7. Pregnancy or lactation\n8. Unable to provide consent and comply with follow-up visits\n9. Listed for lung, heart or heart\u002Flung transplantation\n10. Myocardial infarction or acute coronary syndrome within 90 days of screening\n11. Enrolled in another interventional trial\n12. Planned cardiac or thoracic surgical intervention in the next 6 months.\n13. Known hypersensitivity to empagliflozin or ranolazine.\n14. Concurrent treatment with:\n\n    * strong inhibitors of Cytochrome P450 3A4 (CYP 3A4), (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, nelfinavir, ritonavir, indinavir, saquinavir and grapefruit juice)\n    * class IA antiarrhythmics (e.g., quinidine, procainamide, disopyramide) or class III antiarrhythmics (e.g., sotalol, ibutilide, amiodarone, dronedarone)\n    * inducers of CYP 3A4 (e.g., rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort)\n15. Congenital long QT syndrome or a QTc interval \\>500 ms",{"count":220,"type":22},30,[25],"The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomized trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.",[121,29,28],[121,29,28,225,226],"Empagliflozin","Ranolazine","2025-09-16",{"date":229,"type":38},"2025-09-18",{"date":231,"type":38},"2025-07-15",{"date":233,"type":22},"2026-12",{"name":235,"class":45},"University of Alberta",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":18,"minAge":243,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":255,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":266},"100501442","effects-branch-pa-stenting-d-tga-tof-and-ta-100501442","NCT05809310","Effects Branch PA Stenting d-TGA, ToF and TA","The Effects of Branch Pulmonary Artery Stenting in d-TGA, ToF and TA: a Randomized Control Trial","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* Patients with d-TGA post ASO, ToF or TA\n* ≥8 years\n\nExclusion Criteria:\n\nOne or more of the following inclusion criteria:\n\n* All class IIa indications for a branch PA intervention:\n* Persistent decreased RV function (based on gold standard CMR)\n\n  * \\\u003C18 years RVEF ≤55% (28)\n  * ≥18 years RVEF\\\u003C50% (29)\n* Progressive tricuspid regurgitation (TR) (≥moderate)\n* Isolated bifurcation stenosis:\n\n  * Significant unilateral stenosis (≥50%)\n  * Borderline bilateral PA stenosis (40-70%)\n* Unbalanced perfusion (≤35\u002F65%)\n* RV\u002FLV pressure ratio \\> 2\u002F3 based on echocardiography\n* Reduced lung perfusion or decreased objective exercise capacity (based of gold standard VO2 max during CPET)\n\n  * \\\u003C18 years VO2 peak \\\u003C35 mL∙kg-1∙min-1 (boys) VO2 peak \\\u003C30 mL∙kg-1∙min-1 (girls) (30)\n  * ≥18 years VO2 peak \\\u003C27 mL∙kg-1∙min-1 (men) VO2 peak \\\u003C19 mL∙kg-1∙min-1 (women) (31)","8 Years",{"count":245,"type":22},56,[117],"The goal of this randomized controlled trial is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA.\n\nThe main question\\[s\\] it aims to answer are:\n\nThe primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions.\n\nParticipants will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht\u002FWKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions.\n\nResearchers will compare the difference in VO2 max (% predicted) between the interventional group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo a percutaneous intervention for a PA stenosis) and the control group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo conservative management)",[249,250,251,252,253,29,254],"Transposition of Great Vessels","Tetralogy of Fallot","Truncus Arteriosus","Pulmonary Artery Stenosis Supravalvular Congenital","Stent Stenosis","Congenital Heart Disease",[256],"Exercise capacity","2025-03-25",{"date":259,"type":38},"2025-03-30",{"date":261,"type":38},"2023-04-18",{"date":263,"type":22},"2027-12-31",{"name":265,"class":45},"UMC Utrecht",4,{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":278,"conditions":279,"keywords":282,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":46},"100453721","phase-4-preoperative-maltodextrins-effect-on-cardiac-function-in-cardiac-surgery-100453721","NCT05188222","Preoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery","The Effect of Preoperative Maltodextrin on Cardiac Function in Cardiac Surgery Patients with Reduced Left Ventricular Ejection Fraction: a Randomized, Controlled, Double-blind, Clinical Trial","Inclusion Criteria:\n\n* 18 years of age or older\n* Presenting for coronary artery bypass grafting surgery\n* Preoperative left ventricular ejection fraction \\\u003C 50%\n* First case of the day (7:30am start time)\n\nExclusion Criteria:\n\n* Dysphagia, gastroparesis\n* Cannot tolerate oral intake\n* Celiac disease\n* Type 1 diabetes",{"count":275,"type":22},70,[277],"PHASE4","A randomized, controlled, double-blinded clinical trial evaluating the effect of the administration of a Maltodextrin solution on cardiac function in patients presenting for coronary artery bypass grafting surgery with a reduced left ventricular ejection fraction.",[280,281,29],"Left Ventricular Dysfunction","Quality of Recovery",[283,284,285,286,287],"Cardiac surgery","Insulin","Maltodextrin","Enhanced Recovery After Surgery","Quality of Recovery After Surgery","2025-02-21",{"date":290,"type":38},"2025-02-24",{"date":292,"type":22},"2025-12-01",{"date":294,"type":22},"2027-03-01",{"name":296,"class":45},"Jewish General Hospital",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":46},"100560048","effects-of-negative-pressure-ventilation-on-right-ventricular-function-in-cardiological-patients-100560048","NCT06572072","Effects of Negative Pressure Ventilation on Right Ventricular Function in Cardiological Patients","Effects of Negative Pressure Ventilation on Right Ventricular Function in Cardiological Patients With Reduced Right Ventricular Function.","Inclusion Criteria:\n\n* patients planned for tricuspidal clipping\n\nExclusion Criteria:\n\n* ventilatory of hemodynamic instability\n* fitting of cuirass not possible\n* unavailability of examiner",{"count":220,"type":22},"Patients receives induction of general anesthesia for interventional tricuspidal clipping and standard monitoring for this procedure including arterial and central venous line and transesophageal ultrasound. A cuirass for extrathoracal negative pressure ventilation is placed onto the chest but not switched on. During usual positive pressure ventilation a ventilatory, a hemodynamic and a 3D full volume ultrasounddataset of the right and left ventricle is recorded and severity of tricuspidal regurgitation examined. Afterwards negative pressure ventilation is started and positive pressure ventilation reduced as far as possible without reduction of tidal volumes. The same dataset of ventilation, hemodynamics and ultrasound is collected again during negative pressure ventilation. Afterwards the cuirass gets removed, study finished and everything proceeds as during standard procedure.",[307,29,308],"Negative Pressure Ventilation","Right Ventricular Failure","2024-08-23",{"date":311,"type":38},"2024-08-26",{"date":313,"type":22},"2024-09-01",{"date":315,"type":22},"2025-09-01",{"name":317,"class":45},"Karlsburg Hospital",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":326,"enrollmentInfo":327,"targetDuration":329,"studyType":57,"phases":4,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":342},"100516269","right-ventricular-dysfunction-in-chronic-heart-failure-100516269","NCT06002321","Right Ventricular Dysfunction in Chronic Heart Failure","Right Ventricular Dysfunction in Chronic Heart Failure: Clinical Laboratory and Echocardiographic Characteristics","RIVED-CHF","Inclusion Criteria:\n\n* All patients with a diagnosis of chronic heart failure made according to the recommendations of the ESC guidelines through the simultaneous presence of signs and symptoms of disease associated with BNP and NT proBNP levels \\> 100 and 300 pg\u002Fml respectively which are associated with a modest increase PAPS \\> 30 mmHg with or without right ventricular dilatation.\n\nExclusion Criteria:\n\n* Patients with dyspnea of non-cardiogenic origin, related to systemic respiratory diseases, pulmonary embolism, patients with primary pulmonary hypertension will be excluded.\n* Patients with heart failure linked to primary valvular pathologies or infiltrative pathologies, secondary and on a genetic basis, patients diagnosed with acute heart failure in non-optimized therapy for at least 3 months will also be excluded. - Patients with systemic inflammatory neoplastic diseases, advanced liver and kidney diseases awaiting transplantation will be excluded.","90 Years",{"count":328,"type":22},1000,"36 Months","The goal of this multi center observational prospective study is to analyze the concordance between the signs and symptoms of RHF and echocardiographic features of RVD in patient with heart failure. The main questions it aims to answer are:\n\n1. to assess the incidence of RVH and RVD in each HF subtypes.\n2. to evaluate prognostic impact ( in terms of cardiovascular mortality and HF hospitalization) of different RVD patterns during a mean followup period of 3 years\n3. To investigate the incidence of different RV maladaptation ( isolated RV dilatation, isolated Pulmonary hypertension, combined pattern) in each HF groups and the related outcome.\n\nParticipants will follow by direct check up visit and\u002For virtual visits every 6 months for a mean follow-up period of 3 years.",[332,29,28],"Chronic Heart Failure","2023-08-18",{"date":335,"type":38},"2023-08-21",{"date":337,"type":22},"2023-09-01",{"date":339,"type":22},"2026-09-01",{"name":341,"class":45},"University of Siena",14,{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":4},"100486970","evaluation-of-right-ventricular-function-post-mitral-valve-operations-100486970","NCT05620992","Evaluation of Right Ventricular Function Post Mitral Valve Operations","Evaluation of Right Ventricular Function Post Mitral Valve Operations in Patients With Pulmonary Hypertension.","Inclusion Criteria:\n\n* Patients who underwent mitral valve surgeries who also had pulmonary hypertension in the period between March 2019 and March 2022 in Assiut university heart hospital\n\nExclusion Criteria:\n\n* Patients who underwent mitral valve surgeries with normal pulmonary pressure. Patients who had other valve surgeries besides mitral as aortic and\u002For tricuspid valve surgeries. Patients had mitral valve surgeries with other heart conditions that needed another intervention in the same session as CABG for IHD.",{"count":351,"type":22},50,"We aim to determine the function of Right ventricle post mitral valve surgeries in patients with pulmonary hypertension using transthoracic echocardiography3- and 6-months post-operatively to detect the effect of mitral valve surgeries over the RV function whether improving, deteriorating, or not changing at all.",[29],"2023-01-30",{"date":356,"type":38},"2023-02-01",{"date":358,"type":22},"2023-03-01",{"date":360,"type":22},"2026-11-01",{"name":362,"class":45},"Assiut University"]